Concentrations of single-dose meropenem (1 g iv) in bronchoalveolar lavage and epithelial lining fluid.
The concentrations of meropenem were measured in plasma, bronchoalveolar lavage (BAL) and epithelial lining fluid (ELF) 0.5-8 h after the administration of a single 1 g iv dose of meropenem. Thirty-five patients undergoing bronchoscopy were studied. Mean concentrations in plasma, BAL and ELF, respectively, measured by high performance liquid chromatography, were as follows: 0.5 h: 25. 96, 0.14, 5.04 mg/L; 1 h: 14.98, 0.09, 7.07 mg/L; 2 h: 12.01, 0.06, 3.86 mg/L; 4 h: 2.51, 0.04, 2.20 mg/L; 6 h: 0.57, 0, 0.59 mg/L; 8 h: 0.29, 0, 0 mg/L. Throughout the 2 h following infusion, concentrations in ELF exceeded the MIC90 for all nosocomial and community-acquired respiratory pathogens, including Pseudomonas aeruginosa (3.05 mg/L), Haemophilus influenzae (0.16 mg/L) and penicillin-resistant Streptococcus pneumoniae (0.86 mg/L). These results support the clinical efficacy of meropenem in the treatment of a wide range of pulmonary infections.
Allegranzi
B
B
Departments of Infectious Diseases and Respiratory Medicine, University and Hospital of Verona, Verona, Italy. benealle@yahoo.com
Cazzadori
A
A
Di Perri
G
G
Bonora
S
S
Berti
M
M
Franchino
L
L
Biglino
A
A
Cipriani
A
A
Concia
E
E
D000328:Adult; D001980:Bronchi / Q000378:metabolism*; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry*; D001999:Bronchoscopy; D002851:Chromatography, High Pressure Liquid; D004848:Epithelium / Q000378:metabolism; D005260:Female; D006801:Humans; D008297:Male; D000077731:Meropenem; D013056:Spectrophotometry, Ultraviolet; D013845:Thienamycins / Q000009:adverse effects / Q000493:pharmacokinetics*
D013845:Thienamycins; D000077731:Meropenem